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At micromolar concentrations, ryanodine interacts with the dihydropyridine receptor of rabbit skeletal muscle transverse 
tubules. Ryanodine displaces pecifically bound PH]PNZOO-1 10 with an apparent inhibition constant of approx. 95 PM 
and inhibits dihydropyridine-sensitive calcium channels in the same preparation with an IC,, of approx. 45 PM. These 
concentrations of ryanodine are approximately three orders of magnitude higher than those required to saturate binding 
of the alkaloid to the ryanodine receptor of sarcoplasmic reticulum and to open the calcium release channel of sarco- 
plasmic reticulum (i.e. 20 nM (1988) J. Gen. Physiol. 92, l-26). Thus at sufficiently high dose, ryanodine may affect SR 
as well as plasma membrane Ca permeabilities. 
Dihydropyridine receptor; Ca*+ channel inhibition; Ryanodine 
1. INTRODUCTION 
The muscle-paralysing alkaloid ryanodine [l] 
binds with nanomolar affinity to a 450 kDa pro- 
tein of the sarcoplasmic reticulum (SR) membrane 
of skeletal muscle, i.e. the ryanodine receptor [2]. 
In the SR membrane, the ryanodine receptor forms 
a channel that is thought to control the Ca 
permeability of the SR membrane during 
excitation-contraction coupling [2]. Ryanodine in 
the nanomolar range (20 nM), opens the Ca release 
channel of SR [3] and this effect explains the in- 
crease in 45Ca efflux rate reported in vesicular 
preparations of SR [4,5] treated with the alkaloid. 
However in many studies in intact and fragmented 
preparations, micromolar instead of nanomolar 
levels of ryanodine are used, mainly to reduce the 
time of onset of the physiological effect [6-81. 
Evidently, the association rate of ryanodine to its 
receptor is exceedingly slow, on the time scale of 
several hours at concentrations commensurable 
with the radioligand binding affinity [9]. We show 
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that ryanodine at micromolar concentrations in- 
terferes with dihydropyridine (DHP) receptors of 
the transverse tubular membrane of rabbit skeletal 
muscle. The alkaloid displaces the dihydropyridine 
[3H]PN200-110 from the DHP receptor and in- 
hibits opening of DHP-sensitive calcium channels 
activated by the DHP agonist BAY K 8644 [lo]. At 
sufficiently high concentration, ryanodine may 
thus produce two opposite effects. It would 
decrease the calcium permeability of the plasma 
membrane and it would increase the calcium 
permeability of the SR membrane. 
2. MATERIALS AND METHODS 
2.1. Transverse tubules and planar bilayer recording 
T-tubule vesicles were prepared from rabbit back and leg 
white muscle as described [lo]. Light muscle microsomes 
sedimenting at the 10/20% sucrose interface were used in all ex- 
periments. T-tubules were resuspended in 0.3 M sucrose, 0.1 M 
KCI, 5 mM Na-Pipes, pH 6.8, and frozen in liquid NZ until use. 
Lipid bilayers were cast from an equimolar mixture of 
phosphatidylethanolamine and phosphatidylserine dissolved in 
decane at a concentration of 20 mg lipid/ml. Lipid solution was 
spread across a 3Otpm diameter polystyrene aperture 
separating two aqueous chambers designated cis and trans. The 
volume of each chamber was 3.0 ml and 3.5 ml, respectively. T- 
tubule vesicles (lo-50rg) were added to the cis solution as 
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described in detail elsewhere [lo]. Cis and truns solutions were: 
cis (internal), 100 mM BaC12, 50 mM NaCl, 10 mM Hepes- 
Tris, pH 7.0; truns (external), 50 mM NaCI, 10 mM Hepes- 
Tris, pH 7.0. 
2.2. Radio&and-binding assays 
Samples of 15-4Opg protein/ml were incubated 15 min at 
room temperature and 60 min at 36°C in 1 ml of 50 mM NaCl, 
10 mM Tris-HCl, pH 7.4, and the required concentration of 
(+)-[methyl-‘H]PN200-110 ( .05-7 nM). Specific binding was 
defined as the amount of radiolabel that could be displaced 
competitively by 1 pM cold PN200-110 or nitrendipine; 
[3H]PN200-1 0 was the last reagent added. For determination 
of the total amount of [‘H]PN200-110, a small aliquot (20 ~1) 
was removed before filtration. Binding was terminated by rapid 
filtration on Whatman GF/B or GF/F glass fiber filters. Filters 
were washed twice with 5 ml of an ice-cold solution containing 
20 mM Tris-HCl, pH 7.2, and 200 mM choline chloride. 
Nonspecific binding to filters was negligible and independent of 
the presence of unlabeled ligand in the incubation medium. 
Radioactivity was measured in 6 ml of a Beckman HP/b scin- 
tillant on a Beckman LS 3801 scintillation counter. All ex- 
periments were performed under dim light to avoid photolysis. 
Inhibition of [‘H]PN200-110 binding by ryanodine was carried 
out using 0.2 nM [‘H]PN200-110 and 2Opg/ml t-tubule pro- 
tein. Receptor occupancy by the radiolabel was 20-30%. Pro- 
tein concentration was determined by the Lowry method using 
bovine serum albumin as standard. 
2.3. Chemicals 
Phosphatidylethanolamine and phosphatidylserine were 
from Avanti Polar Lipids (Birmingham, AL). n-Decane was 
purchased from Aldrich (Milwaukee, WI). (+)-[methyl- 
3H]PN200-110 (71 Ci/mmol) was from New England Nuclear 
(Boston, MA). BAY K 8644 was a gift from Dr Scriabine at 
Miles Institute, New Haven, CT. Ryanodine was purchased 
from Calbiochem (La Jolla, CA). 
3. RESULTS AND DISCUSSION 
T-tubules purified from rabbit skeletal muscle 
are an abundant source of dihydropyridine recep- 
tors for electrophysiological [lo- 131, biochemical 
[14,15], and molecular [16,17] studies. In this 
membrane preparation we have implemented 
single-channel recording of Ca channels using the 
planar bilayer technique [13]. Fig. 1 (control) 
shows dihydropyridine-sensitive Ca channels of 
rabbit t-tubules activated by the DHP agonist BAY 
K 8644 (1 pM). The current carrier is 100 mM Ba2+ 
and the membrane potential is 0 mV. We have 
previously shown that once activated by agonist, 
three types of Ca antagonists namely dihydropyri- 
dines, phenylalkylamines, and benzothiazepines, 
inhibit channel activity at doses similar to those 
reported in vivo [12]. At the concentrations in- 
dicated in each set of traces in fig.1, ryanodine 
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Fig.1. Ryanodine blockade of dihydropyridine-sensitive 
calcium channels of skeletal muscle. Channels in ‘control’ were 
activated by 1 pM BAY K 8644 to the cis compartment [lo]. 
Traces below control are representative of 140 s of channel 
recording at the indicated concentration of ryanodine added to 
the truns compartment. Dose-response curve was constructed 
normalizing PO (0.16 in this particular case) to 100%. Data 
points in the presence of ryanodine were calculated accordingly. 
Solid line is a fit using Hill equation assuming a single binding 
site with a Hill coefficient nH = 0.92 and Ki = 45 PM. 
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progressively decreases the number of channels 
opening per trace and the mean duration of single 
events. A dose-response curve at the bottom of 
fig.1 was constructed by plotting the fraction of 
time in which one or more channels were open, 
relative to control, at the four concentrations 
tested. The apparent Ki of the inhibition was ap- 
prox. 45 PM and the Hill coefficient was nH = 
0.92. Left panel of fig.2 shows the inhibition by 
ryanodine (filled circles) of binding of [3H]PN200- 
110 to the DHP receptor (open circles). Scatchard 
analysis of the same data in the right panel of fig.2 
shows that PN200-110 binds to t-tubules with high 
affinity to a single class of sites (& = 0.6 nM, B,,, 
= 16 pmol/mg protein). Ryanodine (60 ,uM) 
decreases B,, (11 pmol/mg protein) and increases 
the & (1.66 nM) of [3H]PN200-1 0 binding to the 
DHP receptor. Binding parameters and ICSO values 
for channels were obtained from least square 
regression of data from three preparations of t- 
tubules. The complete dose-response curve for 
displacement of specifically bound [3H]PN200-1 0 
by ryanodine is shown in fig.3 (triangles) and a Hill 
plot appears as inset. Ryanodine displaces [3H]- 
PN200-110 with an I&-, = 95 FM and Hill coeffi- 
cient nH = 0.75. At the concentration of DHP 
receptor and [3H]PN200-110 used, receptor oc- 
[3H]PN200- 110, nM 
cupancy by [3H]PN200-110 was less than 20%. 
Therefore the I& for displacement of [3H]- 
PN200- 110 by ryanodine is approximately equal to 
the apparent affinity of ryanodine for the DHP 
receptor. The fact that similar concentrations of 
ryanodine are required to inhibit BAY K 8644- 
activated Ca channels and to displace specifically 
bound [3H]PN200-110 (45 PM vs 95 pM, respec- 
tively) strongly suggests that the electrophysiologi- 
cal inhibition observed in fig.1 arises from displa- 
cement of BAY K 8644 from the DHP receptor. 
Two bIockers of ryanodine receptor channels, 
ruthenium red [3,23] and a related analog tetra- 
mino-palladium [181, also interfere with binding of 
dihydropyridines to the dihydropyridine receptor. 
Displacement of [3H]PN200-110 binding by these 
agents is shown in fig.3, open circles (Pd(NH&) 
and filled circles (ruthenium red). 
The 175 kDa dihydropyridine receptor is a struc- 
tural component of the dihydropyridine-sensitive 
Ca channel [14-171. In skeletal muscle, Ca chan- 
nels are present exclusively in transverse tubules, 
the membrane system that originates from foldings 
of the plasma membrane. High-affinity binding 
sites for ryanodine in skeletal muscle are present in 
the junctional SR membrane, the part of the SR 
that- establishes anatomical contacts with the t- 
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Fig.2. Ryanodine inhibition of [3H]PN200-110 binding to t-tubule vesicles of skeletal muscle. (Left panel) Total binding of 
[‘H]PN200-110 in the absence (open circles) or presence (filled circles) of 60 pM ryanodine in the incubation buffer. T-tubule vesicles 
were incubated 15 min at 22°C and 60 min at 36°C as described under section 2 with increasing concentrations of [-‘H]PNZOO-I 10. 
Nonspecific binding (triangles) was defined as the amount of [‘H]PN200-110 binding not displaced by 1 PM cold nitrendipine. (Right 
panel) Scatchard plot of specifically bound [“H]PN200-110 to t-tubule vesicles. Kd and B max for [3H]PN200-1 10 alone (open circles) 
were 0.66 nM and 16 pmol/mg protein, respectively. In the presence of 60rM ryanodine (filled circles), Kd and B,,, increased to 
1.66 nM and 11 pmol/mg protein, respectively. 
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Fig.3. Displacement of [3H]PN200-110 binding to t-tubule 
vesicles for SR Ca-release channel inhibitors. [‘H]PN200-110 
(0.2 nM) was incubated 15 min at 22°C and 60 min at 36°C as 
described in section 2. Pd(NH& (open circles), ruthenium red 
(triangles), or ryanodine (filled circles) were present at the 
indicated concentrations. Nonspecific binding was estimated at 
each concentration of inhibitor and was defined as the amount 
of binding in the presence of 1 PM nitrendipine. (Inset) Hill plot 
of displacement curves. Specific binding (SB) was normalized to 
1 and plotted as log([l/SB] - 1) at the indicated inhibitor 
concentrations. The slope is nH, the Hill coefficient, and Ki = 
antilog - @aXiS interceptIns). VdUeS of nH and Ki for 
inhibitors are: Pd(NH&, 0.94, 8.6pM; ruthenium red, 0.80, 
41.7 /M; ryanodine, 0.75, 95 PM. 
tubules [2,19]. Binding of ryanodine to junctional 
SR varies widely with Ca [20], adenine nucleotide 
concentration [20] and ionic strength [9]. In our 
hands, in 100,~M Ca, 0.15 M NaCl, pH 7.5, 
binding parameters of ryanodine to its receptor in 
SR are & = 10 nM, B,,, = 20 pmol/mg protein 
[21]. Ryanodine specifically binds to a single 
polypeptide of 350-450 kDa identified as the Ca 
release channel of sarcoplasmic reticulum 
[3,20,22,23]. At low concentrations (< 1 ,uM), 
ryanodine opens the release channel and increases 
45Ca efflux from terminal cisternae SR of skeletal 
and cardiac muscle [4,5]. At higher concentrations 
(> 100 ,uM), ryanodine inhibits Ca release 
presumably by closure of Ca release channels [4]. 
Pessah et al. [9] showed that binding of the 
alkaloid to its receptor is a slow process. The 
association rate of ryanodine binding is in the 
order of ‘5.5 x lo6 M-’ vmin-’ at 30°C which at 
5 nM ryanodine translates into a binding reaction 
with a l1/2 of approx. 30 min [9]. Presumably due 
to this slow onset, micromolar instead of 
nanomolar concentrations of ryanodine are 
typically used in electrophysiological experiments 
in muscle cells [6-81. Our results suggest hat the 
DHP receptor-Ca channel constitutes a low- 
affinity binding site for ryanodine as well as for 
ruthenium red, the classical inhibitor of SR Ca 
release [4,9,23,24]. We conclude that at high 
doses, ryanodine may produce in addition to an ac- 
tivation of SR release channels, an inhibition of 
surface membrane Ca channels. Thus in whole cell 
experiments that use high concentration of 
ryanodine, a multiplicity of effects on Ca gradients 
across the plasma membrane and SR membrane 
are expected and should be taken into con- 
sideration. 
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